The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis

(2014) Carsten Lukas et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis

(2014) Tereza Štecková et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

(2014) Frederik Barkhof et al.   Multiple Sclerosis Journal

Intensive blood pressure reduction in acute intracerebral hemorrhage: A meta-analysis

(2014) G. Tsivgoulis et al.   NEUROLOGY

MRI correlates of disability progression in patients with CIS over 48 months

(2014) Tomas Uher et al.   NeuroImage-Clinical

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

(2013) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

Clinical impact of early brain atrophy in clinically isolated syndromes

(2013) F Pérez-Miralles et al.   Multiple Sclerosis Journal

Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome

(2013) M. L. Stromillo et al.   NEUROLOGY

Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis

(2012) N. Bergsland et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Measurement and clinical effect of grey matter pathology in multiple sclerosis

(2012) Jeroen JG Geurts et al.   LANCET NEUROLOGY

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

(2012) Giancarlo Comi et al.   Multiple Sclerosis Journal

Effect of disease-modifying therapies on brain volume in relapsing–remitting multiple sclerosis: Results of a five-year brain MRI study

(2011) Omar Khan et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

MR Imaging of Gray Matter Involvement in Multiple Sclerosis: Implications for Understanding Disease Pathophysiology and Monitoring Treatment Efficacy

(2010) M. Filippi et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis

(2010) B. Audoin et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cognition in multiple sclerosis: relevance of lesions, brain atrophy and proton MR spectroscopy

(2010) Antonio Giorgio et al.   NEUROLOGICAL SCIENCES

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

(2010) N. De Stefano et al.   NEUROLOGY

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

(2009) Alessandro Liberati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review

(2009) Blandine Grassiot et al.   JOURNAL OF NEUROLOGY

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

(2009) Frederik Barkhof et al.   Nature Reviews Neurology

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY